AR045879A1 - Uso de un antagonista del receptor nk3 para preparar una composicion farmaceutica - Google Patents
Uso de un antagonista del receptor nk3 para preparar una composicion farmaceuticaInfo
- Publication number
- AR045879A1 AR045879A1 ARP020101845A ARP020101845A AR045879A1 AR 045879 A1 AR045879 A1 AR 045879A1 AR P020101845 A ARP020101845 A AR P020101845A AR P020101845 A ARP020101845 A AR P020101845A AR 045879 A1 AR045879 A1 AR 045879A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- ring
- optionally substituted
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 abstract 5
- 102100029409 Neuromedin-K receptor Human genes 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 239000002464 receptor antagonist Substances 0.000 abstract 5
- 229940044551 receptor antagonist Drugs 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 230000003871 intestinal function Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000009935 visceral pain Diseases 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- WZMVQZJKOVPVGZ-XIFFEERXSA-N 1-[2-[(3r)-3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]-4-phenylpiperidine-4-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2C[C@](CCN3CCC(CC3)(C(N)=O)C=3C=CC=CC=3)(CC2)C=2C=C(Cl)C(Cl)=CC=2)=C1 WZMVQZJKOVPVGZ-XIFFEERXSA-N 0.000 abstract 1
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 102220511583 Kappa-casein_N10A_mutation Human genes 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- -1 cyano, carboxy Chemical group 0.000 abstract 1
- 230000001351 cycling effect Effects 0.000 abstract 1
- 125000004188 dichlorophenyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 201000000117 functional diarrhea Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 125000005544 phthalimido group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de un antagonista del receptor NK3 para preparar una composición farmacéutica de aplicación en un método para el tratamiento y/o la profilaxis de estados individualizados por una función intestinal alterada y/o dolor visceral en seres humanos o en mamíferos no humanos, método que comprende la administración de una cantidad efectiva, no tóxica y farmacéuticamente aceptable de dicho antagonista del receptor NK3, en el que la condición comprende una función intestinal alterada y/o dolor visceral se selecciona entre determinados estados del síndrome del intestino irritable, distensión abdominal funcional, estrenimiento funcional, diarrea funcional, otros estados intestinales y dolor abdominal funcional. El antagonista del receptor NK3 puede ser un compuesto de la fórmula (1) o de uno de sus solvatos farmacéuticamente aceptables, o de una de sus sales farmacéuticamente aceptables. Preferentemente dicho antagonista del receptor NK3 es seleccionado entre la lista constituida por óxido de [[(diclorofenil)(trime-toxibenzoil)morfolinil]etil]espiro [benzo(c)tiofenopiperidina], R113281, N10A, N5A1, SR-142801, SSR-146977, Cam-2425 y MDL-105212, o, según convenga, uno de sus derivados farmacéuticamente aceptables. Reivindicación 4: El uso según la reivindicación 1, caracterizado porque dicho antagonista del receptor NK3 es un compuesto de la fórmula (1) o uno de sus solvatos farmacéuticamente aceptables, o de una de sus sales farmacéuticamente aceptables, en la que: Ar es un fenilo opcionalmente sustituido, naftilo o un grupo cicloalcadienilo (C5-7), o un grupo heterocíclico opcionalmente sustituido, solo o fusionado con un anillo, que tiene carácter aromático, que contiene de 5 a 12 átomos en el anillo, y que comprende hasta un máximo de cuatro heteroátomos en el anillo o en cada uno de los anillos, seleccionados entre S, O, N; Res un alquilo (C1-8) lineal o ramificado, cicloalquilo (C3-7), cicloalquilalquilo (C4-7), fenilo o fenilalquilo (C1-6) opcionalmente sustituido, un anillo heteroaromático de5 miembros y opcionalmente sustituido, que comprende hasta 4 heteroátomos seleccionados entre O y N, hidroxialquilo (C1-6), aminoalquilo (C1-6), alquilaminoalquilo (C1-6), di-alquilaminoalquilo (C1-6), acilaminoalquilo (C1-6), alcoxialquilo (C1-6), alquil(C1-6)carbonilo, carboxi, alcoxi (C1-6)carbonilo, alcoxi (C1-6)carbonilalquilo (C1-6), aminocarbonilo, alquil(C1-6)aminocarbonilo, di-alquil(C1-6)aminocarbonilo, alquilo (C1-6)halogenado; o es un grupo -(CH2)p- cuando se cicla sobre Ar, en donde p es 2 o 3; R1 y R2 que pueden ser el mismo grupo o un grupo diferente, de manera independiente son H o un alquilo (C1-6) lineal o ramificado, o juntos forman un grupo -(CH2)n-, en el que n representa 3, 4 o 5; o R1 junto con R forma un grupo -(CH2)q-, en el que q es 2, 3, 4 o 5; R3 y R4, que pueden ser el mismo grupo o un grupo diferente, de manera independiente son H o un alquilo (C1-6) lineal o ramificado, alquenilo (C1-6), arilo, alcoxi (C1-6), hidroxi, halógeno, nitro, ciano, carboxi, carboxamido, sulfonamido, alcoxi (C1-6)carbonilo, trifluorometilo, aciloxi, ftalimido, amino, mono- y di-alquil (C1-6)amino, -O(CH2)r-NT, en el que r es 2, 3 o 4 y T es H o un alquilo (C1-6) o forma con el N adyacente un grupo como se muestra en las fórmulas (2), en el que V y V1 de manera independiente son H u O, y u es 0, 1 o 2; -O(CH2)s-OW en el que s es 2, 3 o 4 y W es H o alquilo (C1-6); hidroxialquilo, alquilamino, mono- o di- alquilaminoalquilo, acilamino, alquilsulfonilamino, aminoacilamino, mono- o di-alquilaminoacilamino; con hasta 4 sustituyentes R3 que están presentes en el núcleo de quinolina; o R4 es un grupo -(CH2)t- cuando se cicla sobre R5 como arilo, en el que t es 1, 2 o 3; R5 es un alquilo (C1-6) lineal o ramificado, cicloalquilo (C3-7), cicloalquilalquilo (C4-7), arilo opcionalmente sustituido, o un grupo heterocíclico opcionalmente sustituido, solo o fusionado a un anillo, que tiene carácter aromático, que contiene de 5 a 12 átomos en el anillo y que comprende hasta 4 heteroátomos en el anillo o en cada uno de los anillos, seleccionados entre S, O y N; X es O, S o N-C:::N.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0112208A GB0112208D0 (en) | 2001-05-18 | 2001-05-18 | New use |
| GB0129268A GB0129268D0 (en) | 2001-12-06 | 2001-12-06 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045879A1 true AR045879A1 (es) | 2005-11-16 |
Family
ID=26246093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101845A AR045879A1 (es) | 2001-05-18 | 2002-05-17 | Uso de un antagonista del receptor nk3 para preparar una composicion farmaceutica |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1387687A4 (es) |
| JP (1) | JP2004534761A (es) |
| KR (1) | KR20040016865A (es) |
| CN (1) | CN1269483C (es) |
| AR (1) | AR045879A1 (es) |
| AU (1) | AU2002303811B2 (es) |
| BR (1) | BR0209662A (es) |
| CA (1) | CA2447063A1 (es) |
| CZ (1) | CZ20033115A3 (es) |
| HU (1) | HUP0400966A2 (es) |
| IL (1) | IL158701A0 (es) |
| MX (1) | MXPA03010509A (es) |
| MY (1) | MY134211A (es) |
| NO (1) | NO20035121L (es) |
| NZ (1) | NZ529462A (es) |
| PE (1) | PE20021067A1 (es) |
| PL (1) | PL367308A1 (es) |
| TW (1) | TWI243678B (es) |
| WO (1) | WO2002094187A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE602004028678D1 (de) | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
| PE20060161A1 (es) * | 2004-03-30 | 2006-05-10 | Smithkline Beecham Corp | Composiciones farmaceuticas secadas por pulverizacion que comprenden talnetant |
| WO2005100997A2 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3) |
| US20080255193A1 (en) * | 2005-09-30 | 2008-10-16 | Jeffrey Brum | Pharmaceutical Composition |
| TW200804288A (en) | 2005-12-12 | 2008-01-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| NO2384318T3 (es) | 2008-12-31 | 2018-04-14 | ||
| KR200452372Y1 (ko) * | 2010-05-14 | 2011-02-22 | 서일수 | 건설용 리프트의 통신선 지지장치 |
| KR101034774B1 (ko) * | 2010-07-30 | 2011-05-17 | (주)챔피온코리아 | 와이어로프를 이용한 리프트 장치 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX366293B (es) | 2012-08-21 | 2019-07-04 | Ardelyx Inc | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| EP3552630A1 (en) | 2013-04-12 | 2019-10-16 | Ardelyx, Inc. | Nhe3-binding compounds for inhibiting phosphate transport |
| CA2909752A1 (en) | 2013-04-19 | 2014-10-23 | Astrazeneca Ab | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| US11242337B2 (en) | 2017-01-09 | 2022-02-08 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| BR112019013963A2 (pt) | 2017-01-09 | 2020-04-28 | Ardelyx Inc | inibidores de antiporte mediado por nhe |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
| AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| CA2291111A1 (en) * | 1997-05-23 | 1998-11-26 | Giuseppe Arnaldo Maria Giardina | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
| AR021354A1 (es) * | 1998-11-20 | 2002-07-17 | Smithkline Beecham Spa | Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica |
-
2002
- 2002-05-16 MY MYPI20021787A patent/MY134211A/en unknown
- 2002-05-17 NZ NZ529462A patent/NZ529462A/en unknown
- 2002-05-17 IL IL15870102A patent/IL158701A0/xx unknown
- 2002-05-17 HU HU0400966A patent/HUP0400966A2/hu unknown
- 2002-05-17 PE PE2002000415A patent/PE20021067A1/es not_active Application Discontinuation
- 2002-05-17 PL PL02367308A patent/PL367308A1/xx not_active Application Discontinuation
- 2002-05-17 CZ CZ20033115A patent/CZ20033115A3/cs unknown
- 2002-05-17 MX MXPA03010509A patent/MXPA03010509A/es not_active Application Discontinuation
- 2002-05-17 CA CA002447063A patent/CA2447063A1/en not_active Abandoned
- 2002-05-17 AU AU2002303811A patent/AU2002303811B2/en not_active Ceased
- 2002-05-17 WO PCT/US2002/015911 patent/WO2002094187A2/en not_active Ceased
- 2002-05-17 JP JP2002590908A patent/JP2004534761A/ja active Pending
- 2002-05-17 BR BR0209662-5A patent/BR0209662A/pt not_active IP Right Cessation
- 2002-05-17 KR KR10-2003-7014960A patent/KR20040016865A/ko not_active Withdrawn
- 2002-05-17 CN CNB028101588A patent/CN1269483C/zh not_active Expired - Fee Related
- 2002-05-17 EP EP02731870A patent/EP1387687A4/en not_active Withdrawn
- 2002-05-17 AR ARP020101845A patent/AR045879A1/es not_active Application Discontinuation
- 2002-05-17 TW TW091110318A patent/TWI243678B/zh active
-
2003
- 2003-11-17 NO NO20035121A patent/NO20035121L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL158701A0 (en) | 2004-05-12 |
| PE20021067A1 (es) | 2003-02-02 |
| AU2002303811B2 (en) | 2005-07-07 |
| CN1509175A (zh) | 2004-06-30 |
| KR20040016865A (ko) | 2004-02-25 |
| PL367308A1 (en) | 2005-02-21 |
| CZ20033115A3 (cs) | 2004-09-15 |
| BR0209662A (pt) | 2004-04-20 |
| WO2002094187A2 (en) | 2002-11-28 |
| CA2447063A1 (en) | 2002-11-28 |
| EP1387687A4 (en) | 2006-07-05 |
| NO20035121D0 (no) | 2003-11-17 |
| WO2002094187A3 (en) | 2003-05-30 |
| MY134211A (en) | 2007-11-30 |
| NO20035121L (no) | 2003-11-17 |
| CN1269483C (zh) | 2006-08-16 |
| EP1387687A2 (en) | 2004-02-11 |
| JP2004534761A (ja) | 2004-11-18 |
| MXPA03010509A (es) | 2004-03-02 |
| TWI243678B (en) | 2005-11-21 |
| HUP0400966A2 (hu) | 2004-08-30 |
| NZ529462A (en) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045879A1 (es) | Uso de un antagonista del receptor nk3 para preparar una composicion farmaceutica | |
| ES2617619T3 (es) | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR | |
| ATE226189T1 (de) | Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker | |
| AR037008A1 (es) | El uso del antagonista del receptor nk-1 para la elaboracion de un medicamento para el tratamiento y/o prevencion de lesiones cerebrales, espinales o neuronales y una composicion farmaceutica que comprende uno o mas de dicho antagonista. | |
| CA2238171A1 (en) | Quinoline derivatives as nk3 antagonists | |
| AP9801238A0 (en) | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists. | |
| AR015595A1 (es) | Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos. | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR015769A1 (es) | Derivados de imidazo piridina que inhiben la secrecion de acido gastrico, procedimiento para la preparacion de dichos derivados, composicion farmaceutica, uso de dichos derivados para la preparacion de medicamentos, y compuestos intermediarios. | |
| AR039127A1 (es) | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| AR036041A1 (es) | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| AR031109A1 (es) | Derivados de acido heteroarilalcanoico, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos para inhibir o antagonizar selectivamente a la alfavbeta3 y alfavbeta5 integrinas | |
| AR048934A1 (es) | Morfolinas | |
| AR030701A1 (es) | Derivados cicloalquilos, composiciones que los comprenden y el uso de los mismos para la manufactura de medicamentos para inhibir o antagonizar de manera selectiva alfav beta 3 y/o alfav beta5 integrinas | |
| SE0101579D0 (sv) | New compounds | |
| AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
| FI851996A0 (fi) | Nya substituerade bis-(4-aminofenyl) -sulfoner, deras framstaellning och deras anvaendning saosom laekemedel. | |
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| PE20251183A1 (es) | Inhibidores de amida heterociclica biciclica de sodio activado por voltaje 1.8 (nav 1.8) para el tratamiento del dolor | |
| AR031486A1 (es) | Derivados de pirimidina | |
| AR044470A1 (es) | Derivados de pirrol sustituidos | |
| HRP20010630B1 (hr) | Derivati 4-heterociklil-sulfonamidil-6-metoksi-5-(2-metoksi-fenoksi)-2-piridil-pirimidina, njihova proizvodnja i upotreba kao endotelin receptor antagonista |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |